Xeris Biopharma Holdings Inc Reports Q3 2026 EPS of $0.06, Revenue Misses Estimates at $107. ...
Recorlev Growth and Raised Guidance Offset a Gvoke Gross-to-Net Adjustment Related Stocks: XERS ,
Recorlev Growth and Raised Guidance Offset a Gvoke Gross-to-Net Adjustment Related Stocks: XERS ,